Memantina Lanoratorio Stada, S.L.

Memantine, the active ingredient in Memantina Lanoratorio Stada, S.L., is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults.

GNH USA supplies Memantina Lanoratorio Stada, S.L. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine acts on the glutamatergic pathway and is used in the management of Alzheimer’s disease and related cognitive disorders. - Alzheimer’s disease (moderate to severe): helps improve cognition and daily functioning. - Dementia associated with Alzheimer’s disease: may slow progression of cognitive decline. - Behavioral disturbances in Alzheimer’s disease: can reduce agitation and aggression.

Memantine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue - Hypertension

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Seizures - Cardiac arrhythmias - Hepatic injury - Suicidal thoughts or behavior - Severe allergic reactions (anaphylaxis)

Memantine should be used with caution in specific patient populations and clinical situations. - Renal impairment: assess renal function before initiating therapy. - Hepatic impairment: monitor liver enzymes periodically. - Cardiovascular disease: observe for changes in blood pressure or heart rhythm. - History of seizures: evaluate seizure risk before treatment. - Concomitant use with other NMDA antagonists: avoid additive neurotoxicity. - Store below 25°C: keep in the original pack, protect from moisture.

Memantine may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Ketamine: additive NMDA antagonism may cause profound CNS depression. - Other NMDA antagonists (e.g., dextromethorphan): heightened central nervous system effects.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible enhancement of hypotensive effect. - Diuretics: may increase risk of dehydration and electrolyte imbalance. - CNS depressants (e.g., benzodiazepines): may amplify dizziness and sedation.